TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05864053

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be administered over a 45-minute period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (2R,6R)-hydroxynorketamine
Description: (2R,6R)-Hydroxynorketamine hydrochloride will be administered over a 45-minute period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered over a 45-minute period.
Study: NCT05809258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supraclavicular block
Description: brachial plexus nerve block by supraclavicular route

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary block
Description: brachial plexus nerve block by axillary route
Study: NCT06372275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Clarification Mobile Application
Description: Participants in the intervention group will be asked to answer a series of values clarification writing prompts related to physical activity once a day over four weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Reflection Mobile Application
Description: Participants in the control group will be administered writing prompts in the same format and frequency as the values intervention, but with prompts focused on self-reflection related to physical activity.
Study: NCT05119868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention based on Mediterranean Diet
Description: A personalized nutritional counseling and a tailored diet, according to Mediterranean dietary pattern, designed on the pre-pregnancy weight, height and trimester of pregnancy provided by certified dietitians.
Study: NCT05519488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rubato Life Music
Description: Participants will listen to music using Rubato Life app at least 45 minutes per day, for a period of 2 weeks coming up to their scheduled restaging appointment (or at least 12 total hours of listening), and for one hour immediately after the appointment. Patients in the Intervention group will wear smartwatches to monitor heart rate variability throughout the study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music of their desire
Description: patients will be asked to listen to a minimum of 45 minutes per day of music (or a total of 12 hours), of their desire, which the participant considers as stress relief music for a period of a 2 weeks (or a total of 12 hours)
Study: NCT05542797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duphastone
Description: dydrogesterone hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duphastone
Description: dydrogesterone hormone
Study: NCT06192992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral heating of 2 feet
Description: Heating of both feet

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No heating
Study: NCT05984264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine 2.5% and prilocaine 2.5% cream in pain management before pleurocentesis.
Description: Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area. The time interval between topical Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) application and pleural aspiration will be 30 min, and 45 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2.5% and prilocaine 2.5% cream in pain management before pleurocentesis.
Description: Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) will be applied at least 30 min before the pleurocentesis on the skin overlying the chosen aspiration site using ultrasound under occlusive dressing over a 5 × 5 cm area. The time interval between topical Pridocaine cream (lidocaine 2.5% and prilocaine 2.5%) application and pleural aspiration will be 30 min, and 45 min.
Study: NCT05839106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1032 injection
Description: Subjects will receive PM1032 by intravenous administration.
Study: NCT05097547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency management involves receiving monetary prizes in exchange for negative urine drug screens.
Study: NCT06521255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitmab was infused intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was infused intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was infused intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin was infused intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin was infused intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was infused intravenously.
Study: NCT05334121

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product consumption
Description: Product with identical characteristics to the experimental product. The product will be consumed every day for 4 weeks. Four intakes of 3g each, separated by three hours each, will be carried out.
Study: NCT05073744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: Nalbuphine hydrochloride injection or morphine hydrochloride injection is used for perioperative tumor ablation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine hydrochloride injection is used for perioperative tumor ablation
Study: NCT05646992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Allotransplantation
Description: Temporary allogenic uterus transplantation from a living donor with the goal of achieving pregnancy and delivering viable baby.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Used as daily immunosuppression. Started at 3mg twice daily (PO) on post-operative Day 1, adjusted to achieve serum trough concentrations of 8-10ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imuran
Description: Used as daily immunosuppresion. 100 mg for total body weight less than 75 kg and 150 mg for total body weight greater than or equal to 75 mgs
Study: NCT05998772

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: Application of 82,5 g of glucose monohydrate solved in 300ml water

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Glucose Tolerance Test
Description: Application of 82,5 g of glucose monohydrate solved in 300ml water

Intervention type: OTHER
Intervention: Placebo Oral Glucose Tolerance Test
Description: Application of 125mg sucralose solved in 300ml water

Intervention type: OTHER
Intervention: Placebo Oral Glucose Tolerance Test
Description: Application of 125mg sucralose solved in 300ml water
Study: NCT05082896

Intervention type: PROCEDURE
Intervention: Type of anesthesia choice
Description: Use of conscious sedation vs. general anesthesia

Intervention type: PROCEDURE
Intervention: Type of anesthesia choice
Description: Use of conscious sedation vs. general anesthesia
Study: NCT05642273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris membrane
Description: oXiris membrane for 24h

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood tests
Description: Blood tests just after randomization (0 h) and at 24 h, 48 h and 7 days

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood tests
Description: Blood tests just after randomization (0 h) and at 24 h, 48 h and 7 days
Study: NCT05597800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab will be administered with ipilimumab, plus 2 cycles of histology-based platinum doublet chemotherapy:~* Squamous histology: carboplatin AUC 6 + paclitaxel 200 mg/m2~* Non-squamous histology: carboplatin AUC 5 or 6 + pemetrexed 500 mg/m2 or cisplatin 75 mg/m2 + pemetrexed 500 mg/m Dosing: nivolumab 360 mg every 3 weeks + ipilimumab 1 mg/kg every 6 weeks (up to maximum 2 years) + histology-based, platinum doublet chemotherapy (every 3 weeks for two cycles).
Study: NCT05815732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Personalized exercise program, with defined modalities, intensity, duration, frequency and progression of the exercise.
Study: NCT00047983

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Canola oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil emulsion
Study: NCT06245161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quicksleeper5
Description: intraosseous anesthesia for dental treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quicksleeper5
Description: intraosseous anesthesia for dental treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quicksleeper5
Description: intraosseous anesthesia for dental treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quicksleeper5
Description: intraosseous anesthesia for dental treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional anesthesia
Description: inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional anesthesia
Description: inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional anesthesia
Description: inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional anesthesia
Description: inferior alveolar nerve block for treating mandibular molars infiltration anesthesia for treating maxillary molars
Study: NCT05534464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Twenty grams of the deuterium (2H) - labelled skimmed milk powder mixed with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. Protein free cookies are served alongside to equal macronutrient composition with the other two protein sources.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sorghum
Description: Twenty grams of the deuterium (2H) - labelled whole grain sorghum cooked with water will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black beans
Description: Twenty grams of the deuterium (2H) - labelled black beans cooked with water and mashed into a puree, will be consumed on one of the three different test days. The meal will be divided in 10 portions, consumed every hour. The 2H-labelled protein source is mixed with free 13C-labelled amino acids as reference. A carbohydrate drink is served alongside to equal macronutrient composition with the other two protein sources.
Study: NCT03644706

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADV7103
Description: Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules to be taken by mouth.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules.
Study: NCT05275751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRPA1-inhibitor
Description: Pharmacological inhibition of TRPA1 during intradermal injection of hot synthetic interstitial fluid
Study: NCT04064021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupunture
Description: Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)
Study: NCT05548868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E4W mobile app
Description: Eating for Wellness (E4W) is a mobile application that analyzes photos of meals taken by the user and determines the nutritional profile. Nutritional content is then directly transmitted to the dietitian.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients will receive standard dietary counselling as part of the weight management program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Patients will receive standard dietary counselling as part of the weight management program.
Study: NCT05308602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: Day 0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: Day 28; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01C
Description: Day 180; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: Day 0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: Day 28; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: Day 180; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA vaccine manufactured by Pfizer or Moderna
Description: Day 0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA vaccine manufactured by Pfizer or Moderna
Description: Day 28; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA vaccine manufactured by Pfizer or Moderna
Description: Day 180; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm inactivated COVID-19 vaccine
Description: Day 0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm inactivated COVID-19 vaccine
Description: Day 28; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sinopharm inactivated COVID-19 vaccine
Description: Day 180; intramuscular injection
Study: NCT05970770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypotension Prediction Index
Description: in addition to standard monitoring, will have hemodynamic monitoring using HemoSphere (Edwards Lifesciences, Irvine, CA; internal memory 60 gigabyte, 10 gigabyte used for operating system) with ClearSight non-invasive hemodynamic monitoring and with the Hypotension Prediction Index software enabled. They will not receive preventive vasopressors but only norepinephrine boluses if Hypotension Prediction Index \>85

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Patients in the HPI group will receive a norepinephrine bolus when HPI is below 85

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Patients in the HPI group will receive a norepinephrine bolus when HPI is below 85
Study: NCT05716854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Subjects receive the Clarithromycin intervention orally according to the following schedule:~Day 1: 1 Clarithromycin 500 mg immediate release (IR) tablet twice (Clarithromycin 500 mg BID).~Day 2: 2 Clarithromycin 500 mg immediate release (IR) tablets twice (Clarithromycin 1000 mg BID).~Day 3: 2 Clarithromycin 500 mg immediate release (IR) tablets once (Clarithromycin 1000 mg QD).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimozide
Description: Subjects receive the Pimozide intervention orally according to the following schedule:~Days 1-3: Pimozide 6 mg immediate release (IR) once per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: Subjects receive matching placebo for treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Subjects receive Moxifloxacin 800 mg orally once on day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobicistat
Description: Subjects receive Cobicistat 450 mg orally once on day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin and Cobicistat
Description: Subjects receive Moxifloxacin 800 mg and Cobicistat 450 mg orally once on day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2)
Description: Subjects receive matching placebo for treatments.
Study: NCT06130891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive sensory motor relearning
Description: Cognitive Exercises:~* Orientation: Checking awareness of date, time, and weather.~* Attention: Tasks like connecting dots or spotting differences.~* Shape Sorting: Sorting objects by size, color, etc.~* Calculation Training: Counting money, beads, basic arithmetic.~* Memory: Recalling objects on a tray, numbers backward, word associations.~Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory motor relearning
Description: Sensory Relearning:~* Discrimination: Identifying textures, shapes, sizes, and temperatures.~* Tactile Recognition: Recognizing objects through touch.~* Proprioception: Matching affected limb's position to unaffected limb's.~Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Relearning
Description: Motor Relearning:~* Task-Specific Training: Grasping, pouring, wiping, screwing, holding objects.~* Progression: Increasing duration, intensity, and resistance. 45 minutes per day, 5 days a week for 6 weeks.
Study: NCT04662788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK cells/Combined Monoclonal Antibodies
Description: Each subject receive NK cells/Combined Monoclonal Antibodies
Study: NCT05959408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of throat swab
Description: Introduction of a cotton swab for self-collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of anal swab
Description: Introduction of a cotton swab for self-collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of first void urine
Description: first void urine collected on urine pot
Study: NCT05964517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascial Distortion Model
Description: Facial Distortion is a manual therapy technique applied by model physiotherapists. It is a deep tissue massage to the fascial tissue.
Study: NCT05538767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside
Description: Treatment with Emodepside 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole 400mg
Description: Treatment with Albendazole 400 mg
Study: NCT06181630

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast milk, plasma, and blood samples
Description: Although this study is non- interventional regarding treatment with ozanimod, the study is considered interventional due to the collection of breast milk and plasma from the lactating women and blood samples from their breastfed infants and the additional diagnostic and monitoring procedures required for the study.
Study: NCT05194267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: tDCS alters brain excitability using a weak electric field induced through two electrodes and could potentially improve symptoms of depression
Study: NCT06011460

Intervention type: DRUG
Intervention: Clozapine
Description: Diagnosis of treatment-resistant depressive episode in the course of bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5).~Age from 18 to 65 years old.